Incyte (INCY) Revenue Growth (3y) (2013 - 2026)
Incyte (INCY) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 79.44% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn | 16.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.32% |
| Dec 31, 2025 | 17.59% |
| Sep 30, 2025 | 18.38% |
| Jun 30, 2025 | 10.07% |
| Mar 31, 2025 | 12.82% |
| Dec 31, 2024 | 10.96% |
| Sep 30, 2024 | 11.86% |
| Jun 30, 2024 | 13.94% |
| Mar 31, 2024 | 13.36% |
| Dec 31, 2023 | 8.68% |
| Sep 30, 2023 | 13.98% |
| Jun 30, 2023 | 11.53% |
| Mar 31, 2023 | 12.46% |
| Dec 31, 2022 | 16.95% |
| Sep 30, 2022 | 14.28% |
| Jun 30, 2022 | 19.81% |
| Mar 31, 2022 | 13.77% |
| Dec 31, 2021 | 17.76% |
| Sep 30, 2021 | 21.82% |
| Jun 30, 2021 | 10.61% |